[go: up one dir, main page]

DE3036390A1 - Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid - Google Patents

Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid

Info

Publication number
DE3036390A1
DE3036390A1 DE19803036390 DE3036390A DE3036390A1 DE 3036390 A1 DE3036390 A1 DE 3036390A1 DE 19803036390 DE19803036390 DE 19803036390 DE 3036390 A DE3036390 A DE 3036390A DE 3036390 A1 DE3036390 A1 DE 3036390A1
Authority
DE
Germany
Prior art keywords
general formula
alkyl
compounds
pyrrolo
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19803036390
Other languages
German (de)
Inventor
Kurt Dr. 5300 Bonn Eger
Haireddin Dr. 5672 Leichlingen Jacobi
Herbert 5100 Aachen Pichler
Hermann Josef Prof. Dr. 5340 Bad Honnef Roth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Troponwerke GmbH
Original Assignee
Troponwerke GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Troponwerke GmbH filed Critical Troponwerke GmbH
Priority to DE19803036390 priority Critical patent/DE3036390A1/en
Publication of DE3036390A1 publication Critical patent/DE3036390A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

derivs. (I) are new, (where R is H, amino, OH, halogen, SH, alkylmercapto, alkoxy, alkylamino, aralkylamino, arylamino, or furfurylamino, the alkyl residues, opt. being substd. by halogen and the aryl residues opt. being substd. by halogen, alkyl, CF3 or alkoxy; and R1 and R2 are alkyl, phenyl, or phenyl substd. by halogen, CF3, alkyl or alkoxy, or R1 and R2 together represent a 2-5C alkylene chain opt. substd. by alkyl). The new cpds. are useful as intermediates for biologically active substances, esp. anti-inflammatory agents.

Description

Neue Pyrrolo-Pyrimidine, . Verfahren zu ihrer HerstellungNew pyrrolo-pyrimidines,. Process for their manufacture

und ihre Verwendung bei der Herstellung von biologischen Wirkstoffen Die vorliegende Erfindung betrifft ein neues chemisch eigenartiges Verfahren zur Herstellung von neuen Pyrrolo-Pyrimidinen die als Zwischenprodukte für die Synthese von biologischen Wirkstoffen, insbesondere von Antiphlogistika verwendet werden können.and their use in the manufacture of biological agents The present invention relates to a new chemically unique process for Production of new pyrrolo-pyrimidines which are used as intermediates for the synthesis can be used by biological agents, in particular by anti-inflammatory drugs can.

Es ist bereits bekannt geworden, sekundäre oder tertiäre Amine zu debenzylieren oder zu dealkylieren. Diese Reaktionen beruhen normalerweise auf der Hydrogenolyse mit Palladiumkatalysatoren oder auf der Reduktion mit Natrium in flüssigem Ammoniak (F.W. Korte, Methodicum Chimicum, 6, S. 598 (1974)). Wenn das Amin Bestandteil eines heterocyclischen Systems isst,so führen diese üblichen Verfahren in den bisher'bekannten Fällen nicht zum Erfolg (T. Denzel, Arch. Pharm. (Weinheim) 307, 177 (1974) und J. Chem. Soc. Perkin 1, 1979, 938-942).It has already become known to use secondary or tertiary amines debenzylate or dealkylate. These reactions are usually based on the Hydrogenolysis with palladium catalysts or on the reduction with sodium in liquid Ammonia (F.W. Korte, Methodicum Chimicum, 6, p. 598 (1974)). When the amine component of a heterocyclic system, these usual processes lead to those previously known Cases not successful (T. Denzel, Arch. Pharm. (Weinheim) 307, 177 (1974) and J. Chem. Soc. Perkin 1, 1979, 938-942).

Es ist weiterhin bekannt, Verbindungen mit heterocyclischem Aminteil mit Selendioxid oder mit Polyphosphorsäure zu defurfurylieren (T. Denzel ot al, Arch. Pharm. (Weinheim) 309, 486 (1976)), Pyrrolo-* Pyrimidine, die in Position 7 benzyliert oder furfuryliert sind, lassen sich jedoch nach diesen bekannten Verfahren nicht in brauchbaren Ausbeuten dealkylieren.It is also known compounds with a heterocyclic amine moiety defurfurylate with selenium dioxide or with polyphosphoric acid (T. Denzel ot al, Arch. Pharm. (Weinheim) 309, 486 (1976)), Pyrrolo- * Pyrimidines, in position 7 are benzylated or furfurylated, however, can be according to these known processes do not dealkylate in useful yields.

Andere Pyrrolo-Pyrimidine sind bereits als Naturstoffe und als synthetisch hergestellte Verbindungen bekannt geworden (E.C. Taylor et al, J. Am. Chem. Soc. 86, 951 (1964)).Other pyrrolo-pyrimidines are already available as natural products and as synthetic compounds prepared become known (E.C. Taylor et al, J. Am. Chem. Soc. 86, 951 (1964)).

Die vorliegende Erfindung betrifft neue Pyrrolo-Pyrimidine der allgemeinen Formel I in welcher R für Wasserstoff, Amino, Hydroxy, Halogen, Mercapto, Alkylmercapto, Alkoxy, Alkylamino, Aralkylamino, Arylamino oder Furfurylamino steht, wobei die genannten Alkylreste gegebenenfalls durch Halogen substituiert sind, und wobei die genannten Arylreste gegebenenfalls substituiert sind durch Halogen, Alkyl, Trifluormethyl oder Alkoxy, und R1 und R2 gleich oder verschieden sind und jeweils für Alkyl oder Phenyl, welches gegebenenfalls durch Halogen, Trifluormethyl, Alkyl oder Alkoxy substituiert ist, stehen oder gemeinsam für eine Alkylenkette mit 2 bis 5 Kohlenstoffatomen stehen, welche gegebenenfalls durch Alkyl substituiert ist.The present invention relates to new pyrrolo-pyrimidines of the general formula I. in which R stands for hydrogen, amino, hydroxy, halogen, mercapto, alkylmercapto, alkoxy, alkylamino, aralkylamino, arylamino or furfurylamino, the alkyl radicals mentioned being optionally substituted by halogen, and the aryl radicals mentioned being optionally substituted by halogen, alkyl, Trifluoromethyl or alkoxy, and R1 and R2 are identical or different and each represent alkyl or phenyl, which is optionally substituted by halogen, trifluoromethyl, alkyl or alkoxy, or together represent an alkylene chain having 2 to 5 carbon atoms, which is optionally substituted by alkyl is.

Von besonderem Interesse sind Verbindungen der allgemeinen Formel I in welcher R für Wasserstoff, Amino, Hydroxy, Chlor, Brom, Mercapto, Alkoxy mit 1 bis 4 Kohlenstoffatomen, Alkylamino oder Alkylmercapto mit jeweils 1 bis 4 Kohlenstoffatomen in den Alkylgruppen oder für einen Furfurylaminorest, einen Benzylamino-oder Phenylaminorest steht, der gegebenenfalls durch Halogen, Trifluormethyl, Alkyl oder Alkoxy mit je 1 bis 4 Kohlenstoffatomen substituiert ist und R1 und R2 gleich oder verschieden sind und jeweils für Alkyl mit 1 bis 4 Kohlenstoffatomen oder Phenyl stehen oder gemeinsam für eine Alkylenkette mit 3 bis 4 Kohlenstoffatomen steht.Compounds of the general formula are of particular interest I in which R stands for hydrogen, amino, hydroxy, chlorine, bromine, mercapto, alkoxy with 1 to 4 carbon atoms, alkylamino or alkyl mercapto each with 1 to 4 carbon atoms in the alkyl groups or for a furfurylamino, benzylamino or phenylamino radical stands, which is optionally replaced by halogen, trifluoromethyl, alkyl or alkoxy with each 1 to 4 carbon atoms is substituted and R1 and R2 are identical or different are and each represent alkyl having 1 to 4 carbon atoms or phenyl or together represent an alkylene chain with 3 to 4 carbon atoms.

Dle erfindung betrifft ebenfalls ein Verfahren zur Iterstellung von Pyrrolo-Pyrimidinen der allgemeinen Formel 1, in welchem Pyrrolderivate der allgemeinen Formel II in welcher R1 und R2 die oben angegebene Bedeutung haben, mit Ameisensäurederivaten der allgemeinen Formel III in welcher R' für eine Aminogruppe oder eine Hydroxylgruppe steht, in Gegenwart von Ameisensäure und gegebenenfalls in Gegenwart von inerten organischen Lösungsmitteln bei erhöhter Temperatur umgesetzt werden zu substituierten Pyrrolo-Pyrimidin-Derivaten der allgemeinen Formel IV in welcher R', R1 und R2 die oben angegebene Bedeutung haben, dadurch gekennzeichnet, daß man die Verbindung der allgemeinen Formel In mit einem Überschuß von Säuren aus der Gruppe konzentrierte Salzsäure, Phosphorsäuren oder Polyphosphorsäure bei Temperaturen zwischen 200C und 1500C, gegebenenfalls in Gegenwart von Wasser dealkyliert, und gegebenenfalls die erhaltenen Verbindungen, in welcher R' eine Hydroxylgruppe bedeutet, mit Phosphoroxychlorid umsetzt, und das entstandene Chlorid nach bekannten Methoden mit Aminverbindungen oder Thiocarboxylverbindungen zu dem entsprechenden Amino- und Mercaptoderivaten des Substituenten R der allgemeinen Formel I umsetzt.The invention also relates to a process for the preparation of pyrrolo-pyrimidines of the general formula 1, in which pyrrole derivatives of the general formula II in which R1 and R2 have the meaning given above, with formic acid derivatives of the general formula III in which R 'stands for an amino group or a hydroxyl group, are reacted in the presence of formic acid and optionally in the presence of inert organic solvents at elevated temperature to give substituted pyrrolo-pyrimidine derivatives of the general formula IV in which R ', R1 and R2 have the meaning given above, characterized in that the compound of the general formula In with an excess of acids from the group of concentrated hydrochloric acid, phosphoric acids or polyphosphoric acid at temperatures between 200C and 1500C, optionally in the presence of Water dealkylates, and optionally the compounds obtained, in which R 'is a hydroxyl group, reacts with phosphorus oxychloride, and the resulting chloride is converted by known methods with amine compounds or thiocarboxyl compounds to give the corresponding amino and mercapto derivatives of the substituent R of general formula I.

Der letzte Verfahrensschritt ist nur erforderlich, wenn der Substituent R in der allgemeinen Formel I eine andere Bedeutung als Hydroxyl oder Amino hat. Die Umsetzung erfolgt analog dem von J. F. Gerster et al. J. Med.The last step is only required if the substituent R in the general formula I has a meaning other than hydroxyl or amino. The implementation takes place analogously to that of J. F. Gerster et al. J. Med.

Chem. 10, 326 (t967) beschriebenen Verfahren.Chem. 10, 326 (t967).

Ein besonders vorteilhaftes Verfahren besteht in der Verwendung von Polyphösphorsäure bei dem Dealkylierungsschritt.A particularly advantageous method consists in the use of Polyphosphoric acid in the dealkylation step.

Die Reaktiontemperatur konn in einem tJrOaren Be reich variiert werden. Man arbeitet im allgemeinen zwischen 20 und 100C, vorzugsweise zwischen 50 und 100°C.The reaction temperature can be varied within a range of 100%. In general, between 20 and 100.degree. C., preferably between 50 and 100.degree. C., are used.

Bei der Durchführung der Dealkylierung setzt man die in Frage kommende Säure in großem Ueberschuß ein. Vorzugsweise wird auf 1 Gew.-Teil der Pyrrolo-Pyrimlt verbindung der allgemeinen Formel IV die in Frage kommende Säure in einem überschuß von 2 bis 25 Cow.-To n, insbesondere von 5 bis 10 Gew.-Teilen eingesetzt. Die Reaktion kann je nach Art der eingesetzten Säure sowohl in Suspension als auch in Lösung durchgeführt werden.When carrying out the dealkylation, the one in question is used Acid in large excess. Preferably, 1 part by weight of the pyrrolo-pyrimlt is used compound of the general formula IV the acid in question in an excess from 2 to 25 cow tons, in particular from 5 to 10 parts by weight, are used. The reaction can, depending on the type of acid used, either in suspension or in solution be performed.

Die Aufarbeitung erfolgt in üblicher Weise durch Verdünnen des Reaktionsansatzes mit Wasser und anschließender Neutralisation mit einer Base, vorzugsweise mit Alkalihydroxyden oder mit konzentrierter Ammoniaklösung. Anschließend wird der ausgefallene Niederschlag aus geeigneten inerten organischen Lösungsmitteln, welche gegebenenfalls mit Wasser gemischt sind , kristallisiert. Als geeignete inerte Lösungsmittel seien beispielsweise genannt, Kohlenwasserstoffe wie Toluol, Benzol, Petrolether, Alkohole wie Methanol, Ethanol oder Butanol.Working up is carried out in the customary manner by diluting the reaction mixture with water and subsequent neutralization with a base, preferably with alkali hydroxides or with concentrated ammonia solution. Then the deposited precipitate from suitable inert organic solvents, which optionally with water are mixed, crystallized. Suitable inert solvents are, for example called, hydrocarbons such as toluene, benzene, petroleum ether, alcohols such as methanol, Ethanol or butanol.

Die vorliegende Erfindung betrifft auch die neuen substituierten Pyrrolo-Pyrimidinderivate der allgemeinen Formel IV in welcher R', R1 und R2 die oben angegebene Bedeutung haben.The present invention also relates to the new substituted pyrrolo-pyrimidine derivatives of the general formula IV in which R ', R1 and R2 have the meaning given above.

Diese Verbindungen der Formel IV sind bisher noch nicht bekanntgeworden, können jedoch nach dem oben angegebenen Verfahren in einfacher Weise hergestellt werden.These compounds of the formula IV have not yet become known, can, however, be prepared in a simple manner by the above-mentioned process will.

Bei Kenntnis des Standes der Technik konnte nicht erwartet werden, daß die Phenylethylgruppe sich bei der Einwirkung.von Säuren von der 7-Position des Pyrrolo-Pyrimidinringes in.Ausbeuten von mehr als 80 % der Theorie abspalten ließ. Im Hinblick auf die Erfahrungen von F.-W Korte, (Methodicum Chimicum 6, Seite 598, (1974)) ist eine Debenzylierung mit Polyphosphorsäure nicht ohne weiteres möglich. Solche Debenzylierungen lassen sich zwar hydrogenolytisch in einigen Fällen mit relativ niederen Ausbeuten durchführen. Eine hydrogenolytische Dealkylierung der allgemeinen Formel IV-konnte jedoch nicht durchgeführt werden. Der Stand.der Technik gab somit keinerlei Hinweis auf das erfindungsgemäße Verfahren. Man hätte vielmehr erwarten müssen, das bei den zum Teil recht hohen Reaktionstempe.raturen durch die Anwesenheit von starken Säuren das heterocyclische Ringsystem göffnet oder zumindest verändert wUrde. Es ist als ausgesprochen Überraschend zu benzeichnen daß man durch die erfindungsgem&ße Dealkylierung die neuen Verbindungen der allgemeinen Formel I in sehr hoher Reinheit und in einer Ausbeute, die deutlich Ueber 80 * der Theorie liegt, erhalten kann.With knowledge of the state of the art, it could not be expected that the phenylethyl group changes from the 7-position when exposed to acids of the pyrrolo-pyrimidine ring in yields of more than 80% of theory let. With regard to the experiences of F.-W Korte, (Methodicum Chimicum 6, p 598, (1974)) debenzylation with polyphosphoric acid is not easily possible. Such debenzylations can be carried out hydrogenolytically in some cases perform relatively low yields. A hydrogenolytic dealkylation of the However, general formula IV could not be carried out. The state of the art thus gave no indication of the method according to the invention. One would rather have have to expect that with the sometimes quite high reaction temperatures by the The presence of strong acids opens or at least opens the heterocyclic ring system changed. It is to be described as extremely surprising that one goes through the dealkylation according to the invention the new compounds of the general formula I in very high Purity and in a yield that is clearly above 80 * based on theory.

Bei der Herstellung von Verbindungen der allgemeinen Formel IV in welcher R' Hydroxyl bedeutet ist es zweckmäßig, als Reaktionspartner der allgemeinen Formel III Ameisensäure in 10 bis 30 molarem Überschuß einzusetzen. Bei der Herstellung von Verbindungen der allgemeinen Formel IV in welcher R' eine Amingruppe bedeutet, wird vorzugsweise Formamid (III) in entsprechendem Überschuß eingesetzt.In the preparation of compounds of the general formula IV in which R 'hydroxyl is useful as a reactant of the general Formula III to use formic acid in a 10 to 30 molar excess. In the preparation of of compounds of the general formula IV in which R 'denotes an amine group, formamide (III) is preferably used in an appropriate excess.

Die als Ausgangsverbindungen verwendeten Pyrrol-Derivate der Formel II lassen sich nach bekannten Methoden herstellen durch Kondensation von Hydroxyketonen wie z.B. Benzoin, Acetoin oder Adipoin mit dem Amin des Phenylethyls in Gegenwart von katalytischen Mengen einer starken Säure wie z.B. Salzsäure oder p-Toluolsulfonsäure, bei erhöhter Temperatur zu oC -Aminoketonen. Diese cr -Aminoketone werden anschließend mit Malonsäuredinitril zu den Verbindungen der allgemeinen Formel II kondensiert. Es hat sich herausgestellt, daß die Verwendung von D- oder L-Phenylethylamin ohne Einfluß auf die Kondensationsreaktion ist. Zweckmäßigerweise kann daher das Racemat eingesetzt werden.The pyrrole derivatives of the formula used as starting compounds II can be prepared by known methods by condensation of hydroxy ketones such as benzoin, acetoin or adipoin with the amine of phenylethyl in the presence of catalytic amounts of a strong acid such as hydrochloric acid or p-toluenesulfonic acid, at elevated temperature to oC -aminoketones. These cr -amino ketones are subsequently condensed with malononitrile to give the compounds of general formula II. It has been found that the use of D- or L-phenylethylamine without Influence on the condensation reaction. Appropriately, therefore, the racemate can be used.

Die Aufarbeitung der pyrrol-Derivate der allgemeinen Formel II erfolgt nach bekannten Methoden durch Abdampfen des Lösungsmittels und Rekristallisation des Rückstandes aus geeigneten Lösungsmitteln.The pyrrole derivatives of the general formula II are worked up according to known methods by evaporation of the solvent and recrystallization the residue from suitable solvents.

Die Pyrrolo-Pyrimidlnderivate der allgemeinen Formel IV sind bisher noch nicht bekannt geworden. Sie lassen sich jedoch nach dem oben angegebenen Reaktionsschema durch Umsetzung der Pyrrolverbindungen der Formel II mit Ameisensäurederivaten der Formel III in Gegenwart von inerten organischen Lösungsmitteln, insbesondere von Dimethylformamid, bei Temperaturen zwischen 80 bis 1300C erhalten. Die Isolierung und Aufarbeitung der Verbindung der Formel IV erfolgt nach üblichen Methoden durch Ausfällen in der Kälte, Abfiltrieren und Rekristallisieren aus geeigneten Lösungsmitteln.The Pyrrolo-Pyrimidlnderivate of the general formula IV are so far not yet known. However, they can be according to the reaction scheme given above by reacting the pyrrole compounds of the formula II with formic acid derivatives of Formula III in the presence of inert organic solvents, in particular of Dimethylformamide, obtained at temperatures between 80 and 1300C. The isolation The compound of the formula IV is worked up by customary methods Precipitation in the cold, filtration and recrystallization from suitable solvents.

Die erfindungsgemäßen. Verbindungen der allgemeinen Formel I stellen wertvolle Ausgangsprodukte für die Synthese von biologisch aktiven Wirkstoffen, insbesondere von Antiphlogistika und von Stoffen mit Wirkung auf das zentrale Nervensystem dar. Aus ihnen lassen sich in einfacher Weise durch Substitution des Stickstoffs in 7-Position unterschiedliche Pyrrolo-Pyrimidinderivate mit wertvollen Eigenschaften herstellen (vgl. DT-OS 28 18 676).The invention. Compounds of general formula I represent valuable starting products for the synthesis of biologically active ingredients, in particular anti-inflammatory drugs and substances that have an effect on the central nervous system from them can be in a simple manner by substitution of nitrogen in the 7-position different pyrrolo-pyrimidine derivatives with valuable properties (see DT-OS 28 18 676).

Neben ihrer Eigenschaft als Ausgangsprodukte für chemische Synthesen besitzen die Verbindungen der allgemeinen Formel I ihrerseits selbst wertvolle pharmakologische Eigenschaften. Sie besitzen z.B.In addition to their properties as starting materials for chemical syntheses The compounds of general formula I themselves have valuable pharmacological properties Properties. You have e.g.

entzündungshemmende Wirkung und eignen sich daher xur Herstsllung von Arzneimittelzubereitungen.anti-inflammatory effect and are therefore suitable for manufacture of pharmaceutical preparations.

Die folgenden Beispiele sollen die Erfindung erläutern ohne sie zu beschränken.The following examples are intended to explain the invention without illustrating it restrict.

Beispiele für die Herstellung von Verbindungen der allgemeinen Formel I 1) 4-Amino-5,6-dimethyl-7H-pyrrolo[2,3-d]-pyrimidin 5,32 g (0,02 Mol) 4-Amino-5,6 dimethyl-7H-7-phenylethylpyrrolo[2,3-d]pyrimidin werden in 80 g Polyphosphorsäure bei 600C drei Stunden gerührt. Nach der Hydrolyse mit Wasser wird mit konzentrierter Ammoniaklösung -neutralisiert. Die. ausgefallenen Kristalle werden mit Wasser gewaschen und aus Ethanol umkristallisiert.Examples of the preparation of compounds of the general formula I 1) 4-Amino-5,6-dimethyl-7H-pyrrolo [2,3-d] -pyrimidine 5.32 g (0.02 mole) 4-amino-5,6 dimethyl-7H-7-phenylethylpyrrolo [2,3-d] pyrimidine are dissolved in 80 g of polyphosphoric acid stirred at 600C for three hours. After hydrolysis with water, it is concentrated with Ammonia solution -neutralized. The. precipitated crystals are washed with water and recrystallized from ethanol.

Fp. 2810C Ausbeute 4,55 g (93,6 % der Theorie) Analog dem vorstehend beschriebenen Beispiel wurde hergestellt: 2) 4-Amino-5,6-diphenyl-7H-pyrroloL2,3-41pyrimidin Fp. 3260C Ausbeute 4,6 g (81,3 % der Theorie) 3) 4-Hydroxy-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin Fp. 362"C Ausbeute 3,10 g (95,1 % der Theorie) 4) 4-Hydroxy-.,6-tetramethylen-7H-pyrroloE,3-d7pyrimidin Fp. 2970C Ausbeute 1,45 g (76,7 * der Theorie) 5) 4-Hydroxy-5,6-diphenyl-7H-pyrrolo[2,3-d]pyrimidin Fp. 3650C Ausbeute 1,95 g (67,9 der Theorie) Beispiel 6 4-Chloro-5,6-dimethyl-7H-pyrrolo[2,3-d] -dpyrimidin 1,83 g (0,01- Mol) 4-Hydroxy-5 ,6-dimethyl-7H-pyrrolo 2,3-d,7pyrimidin werden in 30 ml Phosphoroxychlorid vier Stunden am Rückfluß gekocht. Nach dem Erkalten wird der Überschuß an Lösungsmittel im Vakuum abgezogen, der Rückstand hydrolysiert und aus Ethanol umkristallisiert. Melting point 2810C, yield 4.55 g (93.6% of theory) analogous to that above Example described was prepared: 2) 4-Amino-5,6-diphenyl-7H-pyrroloL2,3-41pyrimidine M.p. 3260C, yield 4.6 g (81.3% of theory) 3) 4-hydroxy-5,6-dimethyl-7H-pyrrolo [2,3-d] pyrimidine Mp. 362 "C, yield 3.10 g (95.1% of theory) 4) 4-Hydroxy -., 6-tetramethylene-7H-pyrroloE, 3-d7pyrimidine M.p. 2970C, yield 1.45 g (76.7 * of theory) 5) 4-hydroxy-5,6-diphenyl-7H-pyrrolo [2,3-d] pyrimidine Melting point 3650C, yield 1.95 g (67.9 of theory). Example 6 4-Chloro-5,6-dimethyl-7H-pyrrolo [2,3-d] -dpyrimidine 1.83 g (0.01 mol) of 4-hydroxy-5, 6-dimethyl-7H-pyrrolo 2,3-d, 7-pyrimidine are refluxed for four hours in 30 ml of phosphorus oxychloride. After cooling down the excess solvent is drawn off in vacuo and the residue is hydrolyzed and recrystallized from ethanol.

Fp. 2480C Ausbeute 1,4 g (77,3% der Theorie) Beispiel 7 4-Benzylamino-5,6-dimethyl-7H-pyrrolo[2,3]pyrimidin 1,;81 g (0,01. Mol) 4-Chloro-5,6-dimethyl-7H-pyrrolo [2,3-d]pyrimidin werden. in einem Überschuß von Benzylamin fünf Stunden am Rückfluß gekocht..Die beim Erkalten ausfallenden Kristalle werden aus Ethanol umkristallisiert.Melting point 2480C, yield 1.4 g (77.3% of theory). Example 7 4-Benzylamino-5,6-dimethyl-7H-pyrrolo [2,3] pyrimidine 1. 81 g (0.01 mol) of 4-chloro-5,6-dimethyl-7H-pyrrolo [2,3-d] pyrimidine will. refluxed in an excess of benzylamine for five hours Crystals which precipitate on cooling are recrystallized from ethanol.

Fp. 2120C Ausbeute 1,7 g (67,9 % der, Theorie) Beispiel 8 4-Mercapto-5,6-dimethyl-7B-pyrrolof2,3-dgpyrimidin 1,81 g (0,01 Mol) 4-Chloro-5,6-dimethyl-7H-pyrrolo [7,3-d]pyrimidin werden mit einem Überschuß an Thioharnstoff in Ethanol vier Stunden unter Rückfluß gekocht. Die beim Erkalten ausfallenden Kristalle werden aus Ethanol umkristallisiert.M.p. 2120C Yield 1.7 g (67.9% of theory) Example 8 4-Mercapto-5,6-dimethyl-7B-pyrrolof2,3-dg-pyrimidine 1.81 g (0.01 mol) of 4-chloro-5,6-dimethyl-7H-pyrrolo [7,3-d] pyrimidine are treated with a Excess thiourea in ethanol refluxed for four hours. The at Crystals which precipitate when cooling down are recrystallized from ethanol.

Fp. 3150C Ausbeute 1,30 g (66,4 % der Theorie) Beispiel 9 4-Furfurylamino-5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin 1,81 g (0,01 Mol) 4-Chlor-5,6-dimethyl-7H-pyrrolo ),3-dZpyrimidin werden mit einem Überschuß an Furfurylamin in Ethanol £ünf Stunden am Rückfluß gekocht. Die beim Erkalten ausfallenden Kristalle werden aus Ethanol umkristallisiert.Mp. 3150C Yield 1.30 g (66.4% of theory) Example 9 4-Furfurylamino-5,6-dimethyl-7H-pyrrolo [2,3-d] pyrimidine 1.81 g (0.01 mol) of 4-chloro-5,6-dimethyl-7H-pyrrolo), 3-dZpyrimidine are mixed with a Excess furfurylamine in ethanol refluxed for five hours. The at Crystals which precipitate when cooling down are recrystallized from ethanol.

Fp. 199°C Ausbeute 1,4 g (57,9 % der Theorie) Analog der vorstehend beschriebenen Verbindung wurde hergestellt: Beispiel 10 4-(p-Bromanilino-)5,6-dimethyl-7H-pyrrolo[2,3-d]pyrimidin Fp. 3080C Ausbeute 1,9 g (60,9 % der Theorie)Mp. 199 ° C, yield 1.4 g (57.9% of theory) Analogue of the compound described above was prepared: Example 10 4- (p-bromoanilino) 5,6-dimethyl-7H-pyrrolo [2,3-d] pyrimidine Mp. 3080C, yield 1.9 g (60.9% of theory)

Claims (8)

Patentansprüche 1. Pyrrolo-Pyrimidine der allgemeinen Formel I in welcher R für Wasserstoff, Amino, Hydroxy, Halogen, Mercapto, Alkylmercapto, Alkoxy, Alkylamino, Aralkylamino, Arylamino oder Furfurylamino steht, wobei die genannten Alkylreste gegebenenfalls durch Halogen substituiert sind, und wobei die genannten Arylreste gegebenenfalls substituiert sind durch Halogen, Alkyl, Trifluormethyl oder Alkoxy, und R1 und R2 gleich oder verschieden sind und jeweils für Alkyl oder Phenyl, welches gegebenenfalls durch Halogen, Trifluormethyl, Alkyl oder Alkoxy substituiert ist, stehen oder gemeinsam für eine Alkylenkette mit 2 bis 5 Kohlenstoffatomen stehen, welche gegebenenfalls durch Alkyl substituiert ist.Claims 1. Pyrrolo-pyrimidines of the general formula I in which R stands for hydrogen, amino, hydroxy, halogen, mercapto, alkylmercapto, alkoxy, alkylamino, aralkylamino, arylamino or furfurylamino, the alkyl radicals mentioned being optionally substituted by halogen, and the aryl radicals mentioned being optionally substituted by halogen, alkyl, Trifluoromethyl or alkoxy, and R1 and R2 are identical or different and each represent alkyl or phenyl, which is optionally substituted by halogen, trifluoromethyl, alkyl or alkoxy, or together represent an alkylene chain having 2 to 5 carbon atoms, which is optionally substituted by alkyl is. 2. Verbindungen der allgemeinen Formel I gemäß Anspruch 1 in welcher R für Wasserstoff, Amino, Hydroxy, Chlor, Brom, Mercapto, Alkoxy mit 1 bis 4 Kohlenstoffatomen, Alkytamino oder Alkylmercapto mit jeweils 1 bis 4 Kohlenstoffatomen in den Alkylgruppen oder für einen Furfurylaminorest, einen Benzylamino- oder Phenylaminorest steht1 dergegebenenfalls durch Halogen Trifluoromethyl, Alkyl oder Alkoxy mit je.tbi 4 Kohlenstoffatomen substituiert ist und v R1 und R2 gleich oder verschieden sind und jeweils für Alkyl mit 1 bis 4 Kohlenstoffatomen oder Phenyl stehen oder gemeinsam für eine Alkylenkette mit 3 bis 4 Koglenstoffatomen steht.2. Compounds of general formula I according to claim 1 in which R for hydrogen, amino, hydroxy, chlorine, bromine, mercapto, alkoxy with 1 to 4 carbon atoms, Alkytamino or alkyl mercapto each with 1 to 4 carbon atoms in the alkyl groups or represents a furfurylamino, benzylamino or phenylamino radical1 if necessary by halogen trifluoromethyl, alkyl or alkoxy with je.tbi 4 Carbon atoms is substituted and v R1 and R2 are the same or different and each represent alkyl having 1 to 4 carbon atoms or phenyl or together represents an alkylene chain with 3 to 4 carbon atoms. 3. Verbindungen der allgemeinen Formel IV in welcher R1 und R2 die im Anspruch 1 angegebene Bedeutung besitzt und für Hydroxyl oder Amino steht.3. Compounds of the general formula IV in which R1 and R2 have the meaning given in claim 1 and represent hydroxyl or amino. 4. Verfahren zur Herstellung von Verbindungen dt allgemeinen Formel I gemäß Anspruch 1, in welchem Pyrrolderivate der allgemeinen Formel II in welcher R1 und R2 die oben angegebene Bedeutung haben, mit Ameisensäurederivaten der allgemeinen Formel III in welcher R für eine Aminogruppe oder eine Hydroxyl gruppe steht, in Gegenwart von Ameisensäure und gegebenenfalls in Gegenwart von inerten organischen Lösungsmitteln bei erhöhter Temperatur umgesetzt werden zu substituierten Pyrrolo-Pyrimidin-Derivaten der allgemeinen Formel IV in welcher R', R1 und R2 die oben angegebene Bedeutung haben, dadurch gekennzeichnet, daß man die Verbindung der allgemeinen Formel IV mit einem Überschuß von Säuren aus der Gruppe konzentrierte Salzsäure, Phosphorsäuren und Polyphosphorsäure bei Temperaturen zwischen 200C und 150°C, gegebenenfalls in Gegenwart von Wasser dealkyliert, und gegebenenfalls die erhaltenen Verbindungen, in welchen R' eine Hydroxylgruppe bedeutet, mit Phosphoroxychlorid umsetzt, und das entstandene Chlorid nach bekannten Methoden mit Aminverbindungen oder Thiocarboxylverbindungen zu den entsprechenden Amlno- und Mercaptoderivaten des Substituenten R der allgemeinen Formel I umsetzt.4. A process for the preparation of compounds dt general formula I according to claim 1, in which pyrrole derivatives of the general formula II in which R1 and R2 have the meaning given above, with formic acid derivatives of the general formula III in which R stands for an amino group or a hydroxyl group, converted in the presence of formic acid and optionally in the presence of inert organic solvents at elevated temperature to give substituted pyrrolo-pyrimidine derivatives of the general formula IV in which R ', R1 and R2 have the meaning given above, characterized in that the compound of the general formula IV with an excess of acids from the group of concentrated hydrochloric acid, phosphoric acids and polyphosphoric acid at temperatures between 200C and 150 ° C, optionally in Dealkylated in the presence of water, and optionally the compounds obtained, in which R 'is a hydroxyl group, reacts with phosphorus oxychloride, and the chloride formed is converted by known methods with amine compounds or thiocarboxyl compounds to give the corresponding amine and mercapto derivatives of the substituent R of the general formula I. 5. Verfahren gemäß Anspruch 4, dadurch gekennzeichnet, daß man für die Dealkylierung Po1yphosphorsäure verwendet und die Reaktion b zwischen 50 und 1000C durchführt.5. The method according to claim 4, characterized in that for the dealkylation uses polyphosphoric acid and the reaction b between 50 and 1000C performs. 6. Verfahren gemäß Anspruch 4, dadurch gekennzeichnet, daß man die Säure im Dealkyiierungsschritt in einem Überschuß von 2 bis 25 Gew.-Teilen bezogen auf die. Verbindung IV einsetzt.6. The method according to claim 4, characterized in that the Acid in the dealkyiation step in an excess of 2 to 25 parts by weight on the. Compound IV begins. 7. Verwendung von. Verbindungen der allgemeinen Formel I, gemäß Anspruch 1 zur Herstellung von Pyrrolo-Pyrimidin-Derivaten, die in 7-Position substituiert sind.7. Use of. Compounds of general formula I according to claim 1 for the preparation of pyrrolo-pyrimidine derivatives which are substituted in the 7-position are. 8. Verwendung von. Verbindungen der allgemeinen Formel I, gemäß Anspruch 1, bei der Herstellung von Arzneimittelwirkstoffen.8. Use of. Compounds of general formula I according to claim 1, in the manufacture of active pharmaceutical ingredients.
DE19803036390 1980-09-26 1980-09-26 Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid Withdrawn DE3036390A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19803036390 DE3036390A1 (en) 1980-09-26 1980-09-26 Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19803036390 DE3036390A1 (en) 1980-09-26 1980-09-26 Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid

Publications (1)

Publication Number Publication Date
DE3036390A1 true DE3036390A1 (en) 1982-05-13

Family

ID=6112948

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19803036390 Withdrawn DE3036390A1 (en) 1980-09-26 1980-09-26 Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid

Country Status (1)

Country Link
DE (1) DE3036390A1 (en)

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595530A (en) * 1983-03-17 1986-06-17 Takeda Chemical Industries, Ltd. Thiodeazapurine derivatives
US4892865A (en) * 1987-12-01 1990-01-09 The Regents Of The University Of Michigan Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
US4927830A (en) * 1988-04-08 1990-05-22 The Regents Of The University Of Michigan Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents
US4968686A (en) * 1988-04-08 1990-11-06 The Regents Of The University Of Michigan Acyclic pyrrolo [2,3-d]pyrimidine analogs as antiviral agents
US5248672A (en) * 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
EP0682027A1 (en) 1994-05-03 1995-11-15 Ciba-Geigy Ag Pyrrolopyrimidine derivatives with antiproliferative action
WO1997032879A1 (en) * 1996-03-06 1997-09-12 Novartis Ag 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINES
USRE36187E (en) * 1988-04-08 1999-04-06 The Regents Of The University Of Michigan Acyclic pyrrolo 2,3-d!pyrimidine analogs as antiviral agents
WO2000017203A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines as protein kinase inhibitors
US6140332A (en) * 1995-07-06 2000-10-31 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US6251911B1 (en) 1996-10-02 2001-06-26 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
WO2001072751A1 (en) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
US6660744B1 (en) 1999-09-17 2003-12-09 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
US7335667B2 (en) * 2004-12-22 2008-02-26 Incyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as Janus kinase inhibitors
US7598257B2 (en) 2005-12-13 2009-10-06 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JP2009542749A (en) * 2006-07-10 2009-12-03 デフェロゲン アクチェンゲゼルシャフト Pyrrolopyrimidine for pharmaceutical composition
US7834022B2 (en) 2007-06-13 2010-11-16 Incyte Corporation Metabolites of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
US8563541B2 (en) 2005-09-22 2013-10-22 Incyte Corporation Azepine inhibitors of Janus kinases
US8604043B2 (en) 2009-05-22 2013-12-10 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
US8648068B2 (en) 2010-02-26 2014-02-11 Boehringer Ingelheim International Gmbh Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US8716303B2 (en) 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8754079B2 (en) 2010-02-26 2014-06-17 Boehringer Ingelheim International Gmbh Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
US8765734B2 (en) 2010-03-10 2014-07-01 Incyte Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US8853193B2 (en) 2010-02-26 2014-10-07 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9487521B2 (en) 2011-09-07 2016-11-08 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9512161B2 (en) 2009-10-09 2016-12-06 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Cited By (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4595530A (en) * 1983-03-17 1986-06-17 Takeda Chemical Industries, Ltd. Thiodeazapurine derivatives
US4892865A (en) * 1987-12-01 1990-01-09 The Regents Of The University Of Michigan Pyrrolo[2,3-d]pyrimidine nucleosides as antiviral agents
USRE36187E (en) * 1988-04-08 1999-04-06 The Regents Of The University Of Michigan Acyclic pyrrolo 2,3-d!pyrimidine analogs as antiviral agents
US4927830A (en) * 1988-04-08 1990-05-22 The Regents Of The University Of Michigan Acyclic pyrrolo[2,3-D]pyrimidine analogs as antiviral agents
US4968686A (en) * 1988-04-08 1990-11-06 The Regents Of The University Of Michigan Acyclic pyrrolo [2,3-d]pyrimidine analogs as antiviral agents
US6093698A (en) * 1990-11-01 2000-07-25 The Regents Of The University Of Michigan Polysubstituted benzimidazoles as antiviral agents
US5712255A (en) * 1990-11-01 1998-01-27 The Regents Of The University Of Michigan Treatment of herpes infections with polysubstituted benzimidazoles
US5574058A (en) * 1990-11-01 1996-11-12 The Regents Of The University Of Michigan Polysubstituted benzimidazoles as antiviral agents
US5646125A (en) * 1990-11-01 1997-07-08 The Regents Of The University Of Michigan Polysubstituted benzimidazoles as antiviral agents
US5654283A (en) * 1990-11-01 1997-08-05 The Regents Of The University Of Michigan Polysubstituted benzimidazoles as antiviral agents
US5665709A (en) * 1990-11-01 1997-09-09 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
US5248672A (en) * 1990-11-01 1993-09-28 The Regents Of The University Of Michigan Polysubstituted benzimidazole nucleosides as antiviral agents
US5360795A (en) * 1990-11-01 1994-11-01 The Regents Of The University Of Michigan Polysubstituted benzimidazoles as antiviral agents
US5705490A (en) * 1990-11-01 1998-01-06 The Regents Of The University Of Michigan Polysubstituted benzimidazoles as antiviral agents
US5686457A (en) * 1994-05-03 1997-11-11 Novartis Corporation Pyrrolopyrimidine derivatives having pharmacological activity
AU695244B2 (en) * 1994-05-03 1998-08-13 Novartis Ag Pyrrolopyrimidine derivatives having pharmacological activity
US6096749A (en) * 1994-05-03 2000-08-01 Novartis Corporation Pyrrolopyrimidine derivatives having pharmacological activity
EP0682027A1 (en) 1994-05-03 1995-11-15 Ciba-Geigy Ag Pyrrolopyrimidine derivatives with antiproliferative action
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
US6140332A (en) * 1995-07-06 2000-10-31 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
WO1997032879A1 (en) * 1996-03-06 1997-09-12 Novartis Ag 7-ALKYL-PYRROLO[2,3-d]PYRIMIDINES
US6251911B1 (en) 1996-10-02 2001-06-26 Novartis Ag Pyrimidine derivatives and processes for the preparation thereof
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
WO2000017203A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines as protein kinase inhibitors
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6660744B1 (en) 1999-09-17 2003-12-09 Abbott Gmbh & Co. Kg Pyrazolopyrimidines as therapeutic agents
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
WO2001072751A1 (en) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
US8053433B2 (en) 2004-12-22 2011-11-08 Ineyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
US9090611B2 (en) 2004-12-22 2015-07-28 Incyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
US9580419B2 (en) 2004-12-22 2017-02-28 Incyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors
US8741895B2 (en) 2004-12-22 2014-06-03 Incyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors
US9879010B2 (en) 2004-12-22 2018-01-30 Incyte Holdings Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b] pyrimidin-5-yl-amines as Janus kinase inhibitors
US7335667B2 (en) * 2004-12-22 2008-02-26 Incyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as Janus kinase inhibitors
US8445488B2 (en) 2004-12-22 2013-05-21 Incyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as Janus kinase inhibitors
US8835423B2 (en) 2005-09-22 2014-09-16 Incyte Corporation Azepine inhibitors of janus kinases
US8563541B2 (en) 2005-09-22 2013-10-22 Incyte Corporation Azepine inhibitors of Janus kinases
US7598257B2 (en) 2005-12-13 2009-10-06 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US9814722B2 (en) 2005-12-13 2017-11-14 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US8541425B2 (en) 2005-12-13 2013-09-24 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US8946245B2 (en) 2005-12-13 2015-02-03 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US10398699B2 (en) 2005-12-13 2019-09-03 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US10639310B2 (en) 2005-12-13 2020-05-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9974790B2 (en) 2005-12-13 2018-05-22 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US9079912B2 (en) 2005-12-13 2015-07-14 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase inhibitors
US8415362B2 (en) 2005-12-13 2013-04-09 Incyte Corporation Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US8530485B2 (en) 2005-12-13 2013-09-10 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US11331320B2 (en) 2005-12-13 2022-05-17 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9662335B2 (en) 2005-12-13 2017-05-30 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as janus kinase inhibitors
US11744832B2 (en) 2005-12-13 2023-09-05 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US9206187B2 (en) 2005-12-13 2015-12-08 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-B] pyridines and pyrrolo[2,3-B] pyrimidines as Janus kinase
US8933086B2 (en) 2005-12-13 2015-01-13 Incyte Corporation Heteroaryl substituted pyrrolo[2,3-B]pyridines and pyrrolo[2,3-B]pyrimidines as Janus kinase inhibitors
JP2009542749A (en) * 2006-07-10 2009-12-03 デフェロゲン アクチェンゲゼルシャフト Pyrrolopyrimidine for pharmaceutical composition
US8697713B2 (en) 2006-07-10 2014-04-15 Boehringer Ingelheim International Gmbh Pyrrolopyrimidines for pharmaceutical compositions
US8841318B2 (en) 2006-12-22 2014-09-23 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
US8513270B2 (en) 2006-12-22 2013-08-20 Incyte Corporation Substituted heterocycles as Janus kinase inhibitors
US10016429B2 (en) 2007-06-13 2018-07-10 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US9376439B2 (en) 2007-06-13 2016-06-28 Incyte Corporation Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8889697B2 (en) 2007-06-13 2014-11-18 Incyte Corporation Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US7834022B2 (en) 2007-06-13 2010-11-16 Incyte Corporation Metabolites of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8722693B2 (en) 2007-06-13 2014-05-13 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US11213528B2 (en) 2007-06-13 2022-01-04 Incyte Holdings Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10463667B2 (en) 2007-06-13 2019-11-05 Incyte Incorporation Metabolites of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8829013B1 (en) 2007-06-13 2014-09-09 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US10610530B2 (en) 2007-06-13 2020-04-07 Incyte Corporation Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8822481B1 (en) 2007-06-13 2014-09-02 Incyte Corporation Salts of the janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8420629B2 (en) 2008-03-11 2013-04-16 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US9216984B2 (en) 2009-05-22 2015-12-22 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane—or heptane-nitrile as JAK inhibitors
US9334274B2 (en) 2009-05-22 2016-05-10 Incyte Holdings Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8604043B2 (en) 2009-05-22 2013-12-10 Incyte Corporation 3-[4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
US9623029B2 (en) 2009-05-22 2017-04-18 Incyte Holdings Corporation 3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]octane- or heptane-nitrile as JAK inhibitors
US8716303B2 (en) 2009-05-22 2014-05-06 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US9512161B2 (en) 2009-10-09 2016-12-06 Incyte Corporation Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-D]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8853193B2 (en) 2010-02-26 2014-10-07 Boehringer Ingelheim International Gmbh Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
US8648068B2 (en) 2010-02-26 2014-02-11 Boehringer Ingelheim International Gmbh Heterocycloalkyl-containing thienopyrimidines for pharmaceutical compositions
US8754079B2 (en) 2010-02-26 2014-06-17 Boehringer Ingelheim International Gmbh Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
US9999619B2 (en) 2010-03-10 2018-06-19 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US10695337B2 (en) 2010-03-10 2020-06-30 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US11285140B2 (en) 2010-03-10 2022-03-29 Incyte Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US8765734B2 (en) 2010-03-10 2014-07-01 Incyte Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US9464088B2 (en) 2010-03-10 2016-10-11 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as JAK1 inhibitors
US11571425B2 (en) 2010-05-21 2023-02-07 Incyte Corporation Topical formulation for a JAK inhibitor
US12226419B2 (en) 2010-05-21 2025-02-18 Incyte Corporation Topical formulation for a JAK inhibitor
US10869870B2 (en) 2010-05-21 2020-12-22 Incyte Corporation Topical formulation for a JAK inhibitor
US10758543B2 (en) 2010-05-21 2020-09-01 Incyte Corporation Topical formulation for a JAK inhibitor
US11590136B2 (en) 2010-05-21 2023-02-28 Incyte Corporation Topical formulation for a JAK inhibitor
US11219624B2 (en) 2010-05-21 2022-01-11 Incyte Holdings Corporation Topical formulation for a JAK inhibitor
US8933085B2 (en) 2010-11-19 2015-01-13 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US10640506B2 (en) 2010-11-19 2020-05-05 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as JAK inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
US9993480B2 (en) 2011-02-18 2018-06-12 Novartis Pharma Ag mTOR/JAK inhibitor combination therapy
US9611269B2 (en) 2011-06-20 2017-04-04 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9023840B2 (en) 2011-06-20 2015-05-05 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US10513522B2 (en) 2011-06-20 2019-12-24 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US11214573B2 (en) 2011-06-20 2022-01-04 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US8691807B2 (en) 2011-06-20 2014-04-08 Incyte Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
US9359358B2 (en) 2011-08-18 2016-06-07 Incyte Holdings Corporation Cyclohexyl azetidine derivatives as JAK inhibitors
US9487521B2 (en) 2011-09-07 2016-11-08 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US9718834B2 (en) 2011-09-07 2017-08-01 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US10166191B2 (en) 2012-11-15 2019-01-01 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11337927B2 (en) 2012-11-15 2022-05-24 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US11896717B2 (en) 2012-11-15 2024-02-13 Incyte Holdings Corporation Sustained-release dosage forms of ruxolitinib
US10874616B2 (en) 2012-11-15 2020-12-29 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11576865B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US11576864B2 (en) 2012-11-15 2023-02-14 Incyte Corporation Sustained-release dosage forms of ruxolitinib
US9714233B2 (en) 2013-03-06 2017-07-25 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US8987443B2 (en) 2013-03-06 2015-03-24 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US9221845B2 (en) 2013-03-06 2015-12-29 Incyte Holdings Corporation Processes and intermediates for making a JAK inhibitor
US11045421B2 (en) 2013-08-07 2021-06-29 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US10561616B2 (en) 2013-08-07 2020-02-18 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US9655854B2 (en) 2013-08-07 2017-05-23 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US12151026B2 (en) 2013-08-07 2024-11-26 Incyte Corporation Sustained release dosage forms for a JAK1 inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US11278541B2 (en) 2017-12-08 2022-03-22 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US10899736B2 (en) 2018-01-30 2021-01-26 Incyte Corporation Processes and intermediates for making a JAK inhibitor
US11304949B2 (en) 2018-03-30 2022-04-19 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
US12280054B2 (en) 2018-03-30 2025-04-22 Incyte Corporation Treatment of hidradenitis suppurativa using JAK inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Similar Documents

Publication Publication Date Title
DE3036390A1 (en) Antiinflammatory intermediate 7H-pyrrolo-(2,3-D)-pyrimidine derivs. - prepd. by dealkylation of 7-phenyl:ethyl derivs. by reaction with hydrochloric, phosphoric or poly:phosphoric acid
DE2847693A1 (en) METHOD FOR PRODUCING PYRIMIDO- (6,1-A) -ISOCHINOLIN-2-ONES
DE69422795T2 (en) METHOD FOR PRODUCING 9-AMINO CAMPTOTHECIN
DE2858259C2 (en) 9,10-Dimathoxy-2,3,6,7-tetrahydro-4-H-pyrimido- (6,1-a) -isoquinolin-4-one derivatives and process for their preparation
DE1197466B (en) Process for the preparation of new 5, 6, 7, 8-tetrahydropyrido- [4, 3-d] pyrimidines
DE1620694B2 (en) Process for the preparation of 5-methyl-7-diethylamino-s-triazolo [1,5-a] pyrimidine and its salts with acids
DE2505297B2 (en) Process for the preparation of 2-phenylamino-2-imidazoline derivatives substituted in the 2- and 6-positions of the phenyl nucleus
DE2165056C3 (en) Process for the production of CMnazollnonen
DE2538620A1 (en) PROCESS FOR THE PRODUCTION OF QUINOXALINE AND QUINAZOLINE DERIVATIVES
DD248593A1 (en) PROCESS FOR PREPARING 4-BASED SUBSTITUTED THIENO / 2,3-D / PYRIMIDIN-6-YLCARBOXYANESEESTERS
DE1470367A1 (en) Process for the preparation of 5,6-dihydro-6-oxopyrido [2,3-b] [1,4] benzoxazepines substituted in the 5-position
DD144409A1 (en) PROCESS FOR THE PREPARATION OF 5-ALKYL-2-ROACHED BRACKET ON4-ACYLOXY-PHENYL POOR CLAUSE TO PYRIMIDINES
DE2433176C3 (en) N-cyano-cyano-acetimidate and process for the preparation of 2-halopyrinüdinderivaten
EP0377437B1 (en) Process for the preparation of 2,4-diamino-6-piperidinyl-pyrimidine-3-N-oxide
DE1962261C3 (en) Process for the preparation of 2,6-bis (diethanolamino) -4,8-dipiperidinopyrimido [5,4-d] pyrimidine
DD226893A1 (en) PROCESS FOR PREPARING ARYLAMINOSUBSTITUTED THIENO 2,3-D PYRIMIDINES
DE69127238T2 (en) Process for the preparation of pyrido [1,2-a] pyrimidine derivatives
DE69026638T2 (en) Process for the preparation of pyrido [1,2-a] pyrimidine derivatives
EP0983247B1 (en) Method for producing aromatic bisimides
DE2003043C3 (en) Process for the preparation of 2,6-bis (diethanolamino) -4,8-dipiperidino-pyrimido [5,4d] pyrimidine
DE2760278C2 (en)
DE3707530A1 (en) NEW SUBSTITUTED DIHALOGENPYRIDINE AND METHOD FOR THE PRODUCTION THEREOF AND ITS OTHER IMPLEMENTATION FOR PYRIDINE DICARBONIC ACID DIESTERS
EP0492254A1 (en) N-(tert-Butoxycarbonyl)maleimide
DE1470354C (en) 4H m Dithuno square bracket to 5.4 square bracket to pyrimidine and process ren for their production
DE2755637A1 (en) METHOD FOR PRODUCING BLOOD PRESSURE-REDUCING 6,7-DIMETHOXY-4-AMINO-2 CORNER CLAMP ON 4- (2-FUROYL) -1-PIPERAZINYL CORNER CLAMP TO CHINAZOLINE

Legal Events

Date Code Title Description
8130 Withdrawal